Acute promyelocytic leukemia (APL) is a rare, highly treatable form of acute myeloid leukemia (1). The paucity of studies conducted in Central and South America hint towards a higher prevalence of APL among descendants of Spaniards, as compared to other ethnic groups (2-4). At present, a comprehensive study that delineates potential disparities in APL incidence across Europe has yet been reported.T h e r e f o r e , w e c o n d u c t e d a p o p u l a t i o n -b a s e d study to assess APL incidence across Europe using the RARECAREnet database that holds data from 94 cancer registries across 27 European countries on rare malignancies diagnosed during 2000-2007 (5). To account for completeness and quality, only the pool of 83 cancer registries across 24 European countries that provided data for all cancer types is considered.Age-standardized incidence rates (ASRs) with 95% confidence intervals (CIs) were calculated per 100,000 person-years for the overall cohort and by sex. These rates were standardized as per the European standard population to account for differences in age structure across countries. Furthermore, crude incidence rates with 95%
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.